SynthesisCancer medicine2025
Circulating Tumor Cell Detection for Therapeutic and Prognostic Roles in Breast Cancer.
Synthesis in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Role of circulating tumor cell clusters in breast cancer.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2026Review
- Single-cell transcriptomics in metastatic breast cancer: mapping tumor evolution and therapeutic resistance.Frontiers in genetics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCirculating tumor cells (CTCs) are pivotal liquid biopsy (LB) biomarkers for breast cancer (BC), offering non-invasive insights into tumor progression and metastasis. Despite their clinical promise, CTC detection remains technically challenging due to their extreme rarity in peripheral blood.
methodsThis review systematically evaluates CTC detection methodologies, including immunoaffinity-based approaches and biophysical techniques, which exhibit inherent trade-offs in sensitivity, specificity, and compatibility with downstream analyses. Furthermore, post-isolation molecular characterization methods spanning genomic, transcriptomic, and proteomic analyses are also critically assessed. KEY
findingsCTC molecular profiling holds significant clinical relevance, enabling early diagnosis, prognostic stratification, and real-time monitoring of therapeutic response. Baseline CTC counts or quantitative/phenotypic changes during treatment inform therapeutic decision-making, predict drug resistance, and correlate with recurrence risk and metastatic progression.
conclusionMultimodal analysis integrating CTC morphology, surface markers, and molecular alterations advances precision therapy. However, standardization of detection platforms and clinical validation of CTC-guided protocols remain essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.